News Intercept shares dive after FDA safety alert on liver drug Regulator warns of death risk in patients on higher than recommended dose.
News GSK takes option to develop T-cell therapy with Adaptimmune GlaxoSmithKline has jumped onto the T-cell cancer therapy bandwagon, taking an option with US biotech Adaptimmune to develop a treatment targeting a peptide found on the surface of most can
News Gilead swoops to buy Kite for $12billion Gilead has sealed a deal to acquire cell therapy leader Kite for just under $12 billion.
News Regulators finally back Merck KGaA oral MS drug A long-awaited oral multiple sclerosis drug from Merck KGaA was among a raft of medicines given the green light by Europe's regulator on Friday.
News Gilead's new blockbuster HIV combination nears filing Pharma looks to file bictegravir and F/TAF later this year.
News Ambrosia's sweet $100m round, and other biofinancings Our latest crop of biofinancings has a nine-figure round for Ambrosia, with Pinnacle Medicines, Immutrin, and Gilgamesh Pharma also raising new funds.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
